Top in hem/onc: New leadership at MD Anderson, Opdivo withdrawn from market
Click Here to Manage Email Alerts
The University of Texas MD Anderson Cancer Center recently named Welela Tereffe, MD, as its chief medical executive. It was the top story in hematology/oncology last week.
Another top story was about the withdrawal of Opdivo (nivolumab, Bristol Myers Squibb) as a treatment for small lung cell cancer from the United States market.
Read these and more top stories in hematology/oncology below:
The University of Texas MD Anderson Cancer Center names chief medical executive
The University of Texas MD Anderson Cancer Center’s new chief medical executive joined the institution in 2005 and has served as chief medical officer for 2 years. During that time, she has worked with providers to drive cultural excellence and foster innovation. Read more.
Bristol Myers Squibb withdraws Opdivo for small cell lung cancer indication
Bristol Myers Squibb withdrew nivolumab from the U.S. market for the treatment of patients with small cell lung cancer that progressed after platinum-based chemotherapy and at least one other therapy, according to a press release. Read more.
10 potentially practice-changing studies from San Antonio Breast Cancer Symposium
This year’s virtual San Antonio Breast Cancer Symposium featured hundreds of abstracts that spotlighted advances in basic, translational and clinical research. Read more.
Mentorship leads to research opportunity, ASH spotlight for high school student
As they collaborated on a study — presented at the virtual ASH Annual Meeting and Exposition — of blood types and COVID-19 severity, Shivi Jain, MD, found herself emphasizing one noteworthy detail about her co-author, Shivani Rao. Read more.
FDA grants orphan drug designation to annamycin for soft tissue sarcoma
The FDA granted orphan drug designation to annamycin (Moleculin Biotech) for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release. Read more.